Skip to content

A retrospective analysis of cannabis use in a cohort of mentally ill patients in Sri Lanka and its implications on policy development

Chaturaka Rodrigo, Srina Welgama, Alwis Gunawardana, Chinthaka Maithripala, Gamini Jayananda, Senaka Rajapakse

Substance Abuse Treatment Prevention and Policy July 8, 2010 DOI: 10.1186/1747-597x-5-16 (opens in new tab)

Study at a glance

AI-extracted from the abstract
Characteristics Retrospective analytical cohort study Peer reviewed
Sample size 3,644
Population Psychiatric patients treated at the psychiatry unit of the Provincial General Hospital, Ratnapura, Sri Lanka, over five years (2000-2004)
Duration Five-year record review (2000-2004) with diagnoses assessed by 2009
Topics Cannabis
Citations 8
Key findings Self-reported lifetime cannabis use was strongly associated with being diagnosed with schizophrenia spectrum disorders, with 91.5% of users reporting cannabis use before diagnosis. However, the authors could not identify a particular subgroup of users at increased risk to recommend targeted primary prophylaxis.

Abstract

Background: Several epidemiological studies have shown that cannabis; the most widely used illegal drug in the world, is associated with schizophrenia spectrum disorders (SSD).

Aims: To assess the characteristics of cannabis use and its association with SSD in a cohort of psychiatrically ill patients and discuss the implications for policy development

Methods: This is a retrospective analytical study of a cohort of psychiatric patients who received treatment in the psychiatry unit of the Provincial General Hospital, Ratnapura, Sri Lanka over five years (2000 - 2004). The schizophrenia spectrum disorders defined in this article include schizophrenia and the schizoaffective disorders.

Results: A total of 3644 patient records were analyzed. The percentage of self reported life time cannabis (LTC) use was 2.83% (103, all males). Sixteen percent (576) of the total cohort was diagnosed with SSD by 2009. Male sex and LTC use were significantly associated with SSD (p < 0.01 and 0.001 respectively). In the majority (91.5%), cannabis use preceded the diagnosis. There were 17(16.5%) patients diagnosed as cannabis induced psychosis and 7 (41.2%) of them were subsequently diagnosed as SSD. This group was significantly more likely to have had a past psychiatric consultation, but other demographic and clinical correlates did not differ from the rest of the LTC users.

Conclusions: Self reported LTC use was strongly associated with being diagnosed with SSD. However we could not identify a particular subgroup of users that are at increased risk to recommend targeted primary prophylaxis. The policy implications of this observation are discussed.

Comparable studies

Other observational and cohort studies on cannabis, most cited first.

Study Year Design Participants
High-potency cannabis and the risk of psychosis People with first episode of psychosis and healthy controls from the local population 2009 Case-control study n = 454
Ayahuasca-Assisted Therapy for Addiction: Results from a Preliminary Observational Study in Canada Rural aboriginal population 2013 Observational study
Impaired cognitive performance in drug free users of recreational ecstasy (MDMA) Otherwise healthy young people 2000 Observational
Continued cannabis use and risk of incidence and persistence of psychotic symptoms: 10 year follow-up cohort study Individuals from the general population in Germany aged 14-24 at baseline 2011 Observational cohort n = 1,923
Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases Patients treated for cannabis-induced psychotic symptoms in Denmark between 1994 and... 2005 Observational cohort n = 535

Citations in the library

Explore topics